(Reuters) -Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy ...

马萨诸塞州剑桥市 - 在生物制药板块一项重大举措中，市值1,280亿美元、财务状况稳健的制药巨头Bristol Myers Squibb（纽交所股票代码：BMY）已达成最终协议，将以每股5.00美元的全现金交易收购2seventy bio, Inc.

Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...

CAMBRIDGE, Mass., March 11, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following ...

Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

Bio (TSVT) announced a definitive merger agreement under which Bristol Myers Squibb (BMY) will acquire all of the outstanding shares ...

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

根据最新的SEC文件显示，Kynam Capital Management, LP及其关联实体已出售其在2seventy bio, Inc.（NASDAQ:TSVT）的大量股份。该公司以每股USD 4.93的价格出售了16,238,047股股票，总价值约USD 8005万。此次交易后，相关申报实体不再持有该公司任何股份。值得注意的是，TSVT股价在过去一周上涨了73%，根据 ...

EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...